Mechanism and inhibition of the FabI enoyl-ACP reductase from Burkholderia pseudomallei

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 3, 2011, Pages 564-573

  Liu, Nina ^a   Cummings, Jason E ^b   England, Kathleen ^b,c   Slayden, Richard A ^b   Tonge, Peter J ^a  

^a STONY BROOK UNIVERSITY   (United States)

^b Department of Environmental and Radiological Health Sciences   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

B. pseudomallei; Efflux pumps; Slow onset inhibition

Indexed keywords

BACTERIAL ENZYME; DIPHENYL ETHER DERIVATIVE; FABI ENOYL ACP REDUCTASE; TRICLOSAN; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GENOME; BACTERIAL GROWTH; BACTERIAL STRAIN; BURKHOLDERIA PSEUDOMALLEI; BURKHOLDERIA THAILANDENSIS; CLONING; CONTROLLED STUDY; ENZYME INHIBITION; ESCHERICHIA COLI; FATTY ACID SYNTHESIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STEADY STATE; WILD TYPE;

BACTERIAL PROTEINS; BURKHOLDERIA PSEUDOMALLEI; CLONING, MOLECULAR; ENOYL-(ACYL-CARRIER-PROTEIN) REDUCTASE (NADH); ESCHERICHIA COLI; GENE EXPRESSION; KINETICS; MICROBIAL SENSITIVITY TESTS; RECOMBINANT PROTEINS; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 79951530324     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq509     Document Type: Article

References (46)

1. Gilad J, Harary I, Dushnitsky T et al. Burkholderia mallei and Burkholderia pseudomallei as bioterrorism agents: national aspects of emergency preparedness. Isr Med Assoc J 2007; 9: 499-503.
2. Harding SV, Sarkar-Tyson M, Smither SJ et al. The identification of surface proteins of Burkholderia pseudomallei. Vaccine 2007; 25: 2664-72.
3. Cheng AC, Currie BJ. Melioidosis: epidemiology, pathophysiology, and management. Clin Microbiol Rev 2005; 18: 383-416.
4. Chaowagul W. Recent advances in the treatment of severe melioidosis. Acta Trop 2000; 74: 133-7.
5. White SW, Zheng J, Zhang YM et al. The structural biology of type II fatty acid biosynthesis. Annu Rev Biochem 2005; 74: 791-831.
6. Baldock C, Rafferty JB, Sedelnikova SE et al. A mechanism of drug action revealed by structural studies of enoyl reductase. Science 1996; 274: 2107-10.
7. Heath RJ, Rock CO. Enoyl-acyl carrier protein reductase (fabI) plays a determinant role in completing cycles of fatty acid elongation in Escherichia coli. J Biol Chem 1995; 270: 26538-42.
8. Brinster S, Lamberet G, Staels B et al. Type II fatty acid synthesis is not a suitable antibiotic target for Gram-positive pathogens. Nature 2009; 458: 83-6.
9. Balemans W, Lounis N, Gilissen R et al. Essentiality of FASII pathway for Staphylococcus aureus. Nature 2010; 463: E3-4.
10. Lu H, Tonge PJ. Inhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathway. Acc Chem Res 2008; 41: 11-20.
11. Escalada MG, Harwood JL, Maillard JY et al. Triclosan inhibition of fatty acid synthesis and its effect on growth of Escherichia coli and Pseudomonas aeruginosa. J Antimicrob Chemother 2005; 55: 879-82.
12. Levy CW, Roujeinikova A, Sedelnikova S et al. Molecular basis of triclosan activity. Nature 1999; 398: 383-4.
13. Sivaraman S, Zwahlen J, Bell AF et al. Structure-activity studies of the inhibition of FabI, the enoyl reductase from Escherichia coli, by triclosan: kinetic analysis of mutant. Biochemistry 2003; 42: 4406-13.
14. Lu H, England K, Ende CA et al. Slow-onset inhibition of the Fabl enoyl reductase from Francisella tularensis: residence time and in vivo activity. ACS Chem Biol 2009; 4: 221-31.
15. Ward WHJ, Holdgate GA, Rowsell S et al. Kinetic and structural characteristics of the inhibition of enoyl (acyl carrier protein) reductase by triclosan. Biochemistry 1999; 38: 12514-25.
16. Xu H, Sullivan TJ, Sekiguchi JI et al. Mechanism and inhibition of saFabI, the enoyl reductase from Staphylococcus aureus. Biochemistry 2008; 47: 4228-36.
17. Rawat R, Whitty A, Tonge PJ. The isoniazid-NAD adduct is a slow, tight-binding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: adduct affinity and drug resistance. Proc Natl Acad Sci USA 2003; 100: 13881-6.
18. Sullivan TJ, Truglio JJ, Boyne ME et al. High affinity InhA inhibitors with activity against drug-resistant strains of Mycobacterium tuberculosis. ACS Chem Biol 2006; 1: 43-53.
19. Luckner SR, Liu NN, Ende CWA et al. A slow, tight binding inhibitor of InhA, the enoyl-acyl carrier protein reductase from Mycobacterium tuberculosis. J Biol Chem 2010; 285: 14330-7.
20. Heath RJ, Rock CO. Microbiology-a triclosan-resistant bacterial enzyme. Nature 2000; 406: 145-6.
21. Holden MTG, Titball RW, Peacock SJ et al. Genomic plasticity of the causative agent of melioidosis, Burkholderia pseudomallei. Proc Natl Acad Sci USA 2004; 101: 14240-5.
22. Parikh S, Moynihan DP, Xiao GP et al. Roles of tyrosine 158 and lysine 165 in the catalytic mechanism of InhA, the enoyl-ACP reductase from Mycobacterium tuberculosis. Biochemistry 1999; 38: 13623-34.
23. Hofstein HA, Feng YG, Anderson VE et al. Role of glutamate 144 and glutamate 164 in the catalytic mechanism of enoyl-CoA hydratase. Biochemistry 1999; 38: 9508-16.
24. Lu H, Tonge PJ. Mechanism and inhibition of the FabV enoyl-ACP reductase from Burkholderia mallei. Biochemistry 2010; 49: 1281-9.
25. Reference deleted.
26. Groathouse NA, Brown SE, Knudson DL et al. Isothermal amplification and molecular typing of the obligate intracellular pathogen Mycobacterium leprae isolated from tissues of unknown origins. J Clin Microbiol 2006; 44: 1502-8.
27. England K, Ende CA, Lu H et al. Substituted diphenyl ethers as a broad-spectrum platform for the development of chemotherapeutics for the treatment of tularaemia. J Antimicrob Chemother 2009; 64: 1052-61.
28. Stewart MJ, Parikh S, Xiao GP et al. Structural basis and mechanism of enoyl reductase inhibition by triclosan. J Mol Biol 1999; 290: 859-65.
29. Cleland WW. Kinetics of enzyme-catalyzed reactions with two or more substrates or products. II. Inhibition-nomenclature and theory. Biochim Biophys Acta 1963; 67: 173-87.
30. Segel IH. Enzyme Kinetics. New York: Wiley, 1975.
31. Morrison JF, Walsh CT. The behavior and significance of slow-binding enzyme inhibitors. Adv Enzymol Relat Areas Mol Biol 1988; 61: 201-301.
32. Sivaraman S, Sullivan TJ, Johnson F et al. Inhibition of the bacterial enoyl reductase FabI by triclosan: a structure-reactivity analysis of FabI inhibition by triclosan analogues. J Med Chem 2004; 47: 509-18.
33. Moore RA, DeShazer D, Reckseidler S et al. Efflux-mediated aminoglycoside and macrolide resistance in Burkholderia pseudomallei. Antimicrob Agents Chemother 1999; 43: 465-70.
34. Chan YY, Tan TMC, Ong YA et al. BpeAB-OpRB, a multidrug efflux pump in Burkholderia pseudomallei. Antimicrob Agents Chemother 2004; 48: 1128-35.
35. Quemard A, Sacchettini JC, Dessen A et al. Enzymatic characterization of the target for isoniazid in Mycobacterium tuberculosis. Biochemistry 1995; 34: 8235-41.
36. Rafi S, Novichenok P, Kolappan S et al. Structure of acyl carrier protein bound to FabI, the FASII enoyl reductase from Escherichia coli. J Biol Chem 2006; 281: 39285-93.
37. Jornvall H, Persson B, Krook M et al. Short-chain dehydrogenases/reductases (SDR). Biochemistry 1995; 34: 6003-13.
38. Parikh SL, Xiao GP, Tonge PJ. Inhibition of InhA, the enoyl reductase from Mycobacterium tuberculosis, by triclosan and isoniazid. Biochemistry 2000; 39: 7645-50.
39. Swinney DC. The role of binding kinetics in therapeutically useful drug action. Curr Opin Drug Disc 2009; 12: 31-9.
40. Swinney DC. Biochemical mechanisms of drug action: what does it take for success? Nat Rev Drug Discov 2004; 3: 801-8.
41. Tummino PJ, Copeland RA. Residence time of receptor-ligand complexes and its effect on biological function. Biochemistry 2008; 47: 5481-92.
42. Copeland RA, Pompliano DL, Meek TD. Opinion-drug-target residence time and its implications for lead optimization. Nat Rev Drug Discov 2006; 5: 730-9.
43. Lu H, Tonge PJ. Drug-target residence time: critical information for lead optimization. Curr Opin Chem Biol 2010; 14: 467-74.
44. Zhu L, Lin JS, Ma JC et al. Triclosan resistance of Pseudomonas aeruginosa PAO1 is due to FabV, a triclosan-resistant enoyl-acyl carrier protein reductase. Antimicrob Agents Chemother 2010; 54: 689-98.
45. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W-improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 1994; 22: 4673-80.
46. Waterhouse AM, Procter JB, Martin DMA et al. Jalview Version 2-a multiple sequence alignment editor and analysis workbench. Bioinformatics 2009; 25: 1189-91.